MTOR and neoplasm: Furthermore, Chamoto et al. reported that co-treatment with MHY1485, an mTOR signaling activator, and anti-PD-1 antibody suppresses tumor growth more strongly than treatment with an anti-PD-1 antibody alone; this effect was mediated by activation of cytotoxic T cells [12].